In line with this, we found that neratinib resistance (and cross-resistance to other TKIs) is associated with increased expression of ferroportin-1 in mouse and human models of HER2-positive breast cancer, which may represent a metabolic adaptation to protect resistant cells from iron overload and excessive oxidative stress. Here, SLC40A1 is linked to breast carcinoma.